Form 4: Eli Lilly Executive Lucas Montarce Reports Stock Transactions

Eli Lilly's EVP & CFO, Lucas Montarce, executed transactions involving company stock, including the vesting of restricted stock units and the subsequent sale of shares to cover taxes.

Summary

• Lucas Montarce, EVP & CFO of Eli Lilly, reported transactions involving the company's common stock on November 1, 2024.
• These transactions included the vesting of 1,074 restricted stock units, each representing one share of Eli Lilly common stock.
• Following the vesting, 467.196 shares were sold at a price of $818.93 per share to cover tax obligations.
• After these transactions, Montarce directly owns 11,073.804 shares of Eli Lilly common stock.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing detailing stock transactions by an executive, which is neither positive nor negative in itself.

Industry Context

This is a routine disclosure of stock transactions by a company executive, which is common practice for publicly traded companies. It provides transparency into the executive's holdings and transactions.

Comparison to Industry Standards

• The reporting of stock transactions by executives is a standard practice across all publicly listed companies in the US.
• The use of restricted stock units as part of executive compensation is also a common practice.
• The sale of shares to cover tax obligations is a typical occurrence when restricted stock units vest.

Stakeholder Impact

• The transactions have a minimal impact on shareholders as they are routine and do not indicate any significant change in the company's financial health or executive's confidence.

Key Dates

Keywords

Eli Lilly, LLY, insider trading, stock transaction, restricted stock units, executive compensation, SEC Form 4, Lucas Montarce